FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry, namely to heterocyclic compound of formula (I), as well as to its pharmaceutically acceptable salt and enantiomer, where R1 is a hydrogen atom, phenyl, linear saturated hydrocarbon chain containing 1-5 carbon atoms, cycloalkyl containing 5-6 carbon atoms, or straight saturated hydrocarbon chain containing 1-4 carbon atoms, substituted cycloalkyl containing 3 carbon atoms; R2 is hydrogen atom, hydroxyl, linear saturated hydrocarbon chain containing 1-5 carbon atoms, straight saturated hydrocarbon chain containing 1-4 carbon atoms, substituted cycloalkyl containing 3-7 carbon atoms, oxygen atom, substituted linear saturated hydrocarbon chain containing 1-4 carbon atoms, an oxygen atom, substituted carbonyl, substituted linear saturated hydrocarbon chain containing 1-4 carbon atoms, carbonyl, substituted linear saturated hydrocarbon chain containing 1-4 carbon atoms, or cycloalkyl containing 6 carbon atoms, carbonyl, substituted by oxygen atom, substituted linear saturated hydrocarbon chain containing 1-4 carbon atoms, Carbonyl, substituted monoalcylamino, alkyl which is linear saturated hydrocarbon chain containing 1 carbon atom, carboxyl group, cyano group or amino group, bisubstituted phenyl or linear hydrocarbon chain containing 1-4 carbon atoms; R3 is linear saturated hydrocarbon chain containing 1 carbon atom, substituted phenyl, possibly substituted with one or two groups, selected from halogen and oxygen, substituted linear saturated hydrocarbon chain containing 1 carbon atom; R4 is linear saturated hydrocarbon chain containing 1-4 carbon atoms, substituted imidazole, unsubstituted or substituted linear saturated hydrocarbon chain containing 1 carbon atom; R5 represents hydrogen atom or linear hydrocarbon chain containing 1-4 carbon atoms; X represents oxygen atom or sulphur atom; n, m equals to 1 or 2. Invention also relates to use of formula (I), pharmaceutical and cosmetic compositions based on compound of formula (I).
EFFECT: technical result is obtaining novel heterocyclic compounds, useful as modulators of melanocortin receptors.
21 cl, 2 dwg, 1 tbl, 26 ex
Title | Year | Author | Number |
---|---|---|---|
OXOAZETIDINE DERIVATIVES, METHOD FOR PRODUCING AND USING THEREOF IN MEDICINE AND COSMETIC MEDICINE | 2009 |
|
RU2671189C1 |
OXOAZETIDINE DERIVATIVES, METHOD FOR PRODUCING THEM AND USING THEM IN MEDICINE AND COSMETIC MEDICINE | 2009 |
|
RU2569886C2 |
HETEROARYL COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF AS PROTEIN KINASE INHIBITORS | 2007 |
|
RU2474582C2 |
CONDENSED QUINOLINE DERIVATIVE AND USE THEREOF | 2005 |
|
RU2384571C2 |
OXAZETHYDINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE IN MEDICINE AND COSMETICS | 2012 |
|
RU2624011C2 |
N-HETEROCYCLIC DERIVATIVES AND THEIR APPLYING AS NITROGEN OXIDE SYNTHASE INHIBITOR | 1998 |
|
RU2241708C2 |
8-METHYL-1-PHENYLIMIDAZO[1,5-a]PYRAZINE COMPOUNDS | 2011 |
|
RU2560162C2 |
TECHNETIUM AND RHENIUM COMPLEXES WITH BIS(HETEROARYLS) AND METHODS FOR USING THEM | 2009 |
|
RU2539584C2 |
2-CYANOPYRIMIDINE-4-YL CARBAMATE, OR A UREA DERIVATIVE, OR ITS SALT AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2019 |
|
RU2788740C2 |
3-AMINOPYRROLIDINE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | 2003 |
|
RU2355679C2 |
Authors
Dates
2016-07-10—Published
2009-11-04—Filed